Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key b…
An institutional-grade, numbers-driven thesis on PFE — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 7, 2026, TradersQuant's model rates Pfizer Inc. (PFE) 61/100 with a 12-month base-case forecast of $26.88 — +2.6% versus the current price of $26.20. Pfizer Inc. trades at $26.20 in the Healthcare sector, with a market capitalisation of $149.33B. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month analyst consensus price target for PFE is $26.88, implying +2.6% versus the current price. The model's 12-month scenario range runs from $25.94 (bear) to $30.81 (bull), with a base case of $27.48.
On the fundamentals, Pfizer shows a P/E of 34.6, trailing revenue of $62.58B, revenue growth of -1.6% YoY, a dividend yield of 6.56%. This page also tracks PFE's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
PFE currently carries a TradersQuant composite score of 61/100, which we read as a neutral-to-watch signal. The Wall-Street analyst consensus is "Hold". Our 12-month price target of $26.88 implies +2.6% from $26.20. This is research, not financial advice — always combine it with your own judgement.
The analyst consensus price target for PFE is $26.88, about +2.6% versus the latest price of $26.20. Consensus is based on 39 analysts.
TradersQuant's 12-month model forecast for PFE is a base case of $27.48, ranging from $25.94 (bear) to $30.81 (bull), an expected return of +4.9%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for PFE over the next 12 months is $27.48 in the base case (bear $25.94, bull $30.81), versus today's price of $26.20. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for PFE — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates PFE's fair value at $26.88, implying +2.6% of expected upside versus the current price.
Yes — Pfizer pays a dividend yielding 6.56% (about $1.72 per share annually).
Data and model outputs are for research only and are not financial advice. Figures update continuously.
